Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

AVROBIO, Inc. - Common Stock (NQ: AVRO )

1.400 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jun 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AVROBIO, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Nuwellis (NASDAQ:NUWE) stock moved upwards by 13.6% to $1.25 during Wednesday's pre-market session. The market value of their outstanding shares is at $13.1... 
Via Benzinga
AVROBIO Reports Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis
From AVROBIO, Inc.
Via Business Wire
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, & More
Biotech stocks managed to close the week with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid some big pharma earnings. The sector came... 
Via Talk Markets
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From AVROBIO, Inc.
Via Business Wire
Analyst Ratings For Avrobio
Within the last quarter, Avrobio (NASDAQ:AVRO) has observed the following a... 
Via Benzinga
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big... 
Via Benzinga
AVROBIO Announces the Appointment of Sean O’Bryan as Chief Regulatory Officer
From AVROBIO, Inc.
Via Business Wire
Why Avrobio's Shares Are Plunging Today
Avrobio Inc (NASDAQ: AVRO) has updated its pipeline deprioritizing its Fabry disease clinical program to focus on other clinical-stage studies in the lysosomal... 
Via Benzinga
AVROBIO to Present at Cowen’s 2nd Annual Genetic Medicines Summit
From AVROBIO, Inc.
Via Business Wire
AVROBIO to Present New Data from Phase 1/2 Clinical Trial in Cystinosis at WORLDSymposium™ 2022
From AVROBIO, Inc.
Via Business Wire
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From AVROBIO, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Wednesday
Before 10 am on Wednesday, 99 companies set new 52-week lows. Facts of Interest About Today's 52-Week Lows: Sea (NYSE:SE) was the largest firm by market cap to set a... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2022
Upgrades According to TD Securities, the prior rating for Canada Goose Holdings Inc (NYSE: 
Via Benzinga
45 Biggest Movers From Yesterday
Gainers ATA Creativity Global (NASDAQ: AACG) gained 114.3% to close at $2.55. Hoth Therapeutics, Inc. (NASDAQ: HOTH) surged 85.7% to settle at $1.30 after the company announced... 
Via Benzinga
Mid-Afternoon Market Update: Dow Jumps 250 Points; Avrobio Shares Slide
Toward the end of trading Tuesday, the Dow traded up 0.70% to 36,839.62 while the NASDAQ fell 1.57% to 15,583.77. The S&P also fell, dropping 0.03% to 4,794.93. The U.S. has... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Hoth Therapeutics (NASDAQ: 
Via Benzinga
Dow, S&P 500 Nab Intraday Highs as Bond Yields Rise
The Dow Jones Industrial Average is up 242 points midday, pacing for another record close. The S&P 500 Index also hit an intraday record this morning but has since joined the tech-heavy Nasdaq... 
Via Talk Markets
Mid-Day Market Update: Nasdaq Dips 250 Points; TherapeuticsMD Shares Surge
Midway through trading Tuesday, the Dow traded up 0.66% to 36,827.65 while the NASDAQ fell 1.63% to 15,574.50. The S&P also fell, dropping 0.08% to 4,792.93. The U.S. has the... 
Via Benzinga
34 Stocks Moving In Tuesday's Mid-Day Session
Gainers TherapeuticsMD, Inc. (NASDAQ: TXMD) jumped 31.7% to $0.5185 after it announced that the FDA approved a low dose version of Bijuva, an oral hormone therapy to treat women... 
Via Benzinga
Mid-Morning Market Update: Markets Mostly Higher; ISM Manufacturing Index Drops To 58.7
Following the market opening Tuesday, the Dow traded up 0.74% to 36,857.55 while the NASDAQ fell 0.14% to 15,811.30. The S&P also rose, gaining 0.40% to 4,815.75. The U.S. has... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Plus Therapeutics (NASDAQ:PSTV) shares increased by 68.7% to $1.84 during Tuesday's pre-market session. The market value of their outstanding shares is at $28.... 
Via Benzinga
AVROBIO Reprioritizes Pipeline Programs
From AVROBIO, Inc.
Via Business Wire
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From AVROBIO, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers iSpecimen (NASDAQ:ISPC) stock moved upwards by 115.09% to $21.94 during Friday's regular session. As of 12:30 EST, this security is trading at a volume of 62.8... 
Via Benzinga
AVROBIO Presents Clinician Experience with FAB-GT Clinical Trial and Updated Safety Data for Investigational Gene Therapies in Fabry Disease and Gaucher Disease Type 1
From AVROBIO, Inc.
Via Business Wire
AVROBIO to Present at Two Upcoming Investor Conferences in November
From AVROBIO, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021
Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE: 
Via Benzinga
AVROBIO to Present Clinical and Preclinical Data at the 14th ICIEM Conference
From AVROBIO, Inc.
Via Business Wire
AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From AVROBIO, Inc.
Via Business Wire
AVROBIO Reports Third Quarter 2021 Financial Results and Provides Business Update
From AVROBIO, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.